Retatrutide in Australia — research guide, purity and pricing

Retatrutide is a single-chain synthetic peptide designed to act at three incretin and metabolic receptors — GLP-1, GIP and the glucagon receptor — rather than one. That multi-receptor design is the reason it is studied separately from single-agonist peptides.

It is an investigational compound. It has not been registered by the TGA and is supplied here only as a laboratory reference material.

Peer-reviewed work on Retatrutide sits in the metabolic research literature and examines receptor binding and signalling behaviour, and metabolic endpoints in clinical trial settings run by the compound's developer.

We do not summarise trial outcomes or reproduce endpoint figures here. Search the primary literature directly using the reference links below and read the papers in full.

Lyophilised material is typically reconstituted with bacteriostatic or sterile water added slowly down the vial wall, then swirled rather than shaken to avoid shearing the peptide.

Record the reconstitution volume and date against the lot number so concentration is traceable in your notes.

Lyophilised (freeze-dried) peptides are shipped cold-chain packed and are typically stored at -20°C for long-term storage, or 2-8°C for short periods before reconstitution.

Once reconstituted with bacteriostatic water, vials are generally refrigerated at 2-8°C and protected from light and repeated freeze-thaw cycles.

Every Aussie Peptides vial carries a lot number that maps to a batch Certificate of Analysis, so purity and identity can be recorded alongside your experimental data.

Materials on this site are supplied strictly for in-vitro laboratory research. They are not therapeutic goods, are not approved by the TGA for human use, and are not supplied for human or veterinary consumption.

Purchasers must be 18 or over and are responsible for handling, storing and disposing of research materials in line with their institution's requirements and applicable Australian law.

Nothing on this page is medical advice, a dosing protocol, or a claim of therapeutic benefit. It summarises what the published research literature investigates.